—
C+
C+ The full Closelook — membership. Open the C+ overview

Lantheus Holdings Inc (LNTH) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Lantheus Holdings Inc

LNTH in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Lantheus develops diagnostic and therapeutic products used in imaging and treating heart disease, cancer and other conditions. Its portfolio includes DEFINITY for echocardiography, TechneLite and Xenon-133 for nuclear medicine, and PYLARIFY, a PET imaging agent used to detect prostate cancer. It also markets RELISTOR for opioid-induced constipation and develops several radiopharmaceutical therapy candidates still in testing. The company is based in Bedford, United States.
Where it sits in the stack
Lantheus sits outside our AI build-out index; it belongs to the healthcare sector, within the specialty pharmaceuticals and diagnostic imaging sleeve of our wider universe.
Who it is priced against
Closelook's peer group is not set for this name; the comparison the market draws is with Novartis's radioligand therapy business.
Why Closelook tracks it
Lantheus holds no seat in our indices and carries no Closelook score yet; the diary has not quoted it in any edition.
What the diary watches
Whether its pipeline of radiopharmaceutical imaging and therapy candidates, such as PNT2002 and PNT2003, advances toward approval and adds new revenue lines.

Lantheus Holdings Inc (LNTH) trades on US exchanges.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for LNTH, from the same nightly bakes the boards use. Research diary readings, not advice.

The Street on this name 1 analyst action on the wire · latest: downgrade by B. Riley, 2026-08-17

The Street on this name

Analyst actions and the latest print for LNTH from the Closelook wires — third-party opinions on the record, not our readings.

  • Downgrade B. Riley — Buy → Neutral Downgraded to Neutral from Buy 2026-08-17

1 action on the analyst wire since 2026-08-13: 1 downgrade. Analyst wire → · Earnings wire →

Who it is priced against Drug Manufacturers - Specialty & Generic · US · 8 names with week and year-to-date

Peer group

Drug Manufacturers - Specialty & Generic · US

This name carries no Closelook score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against LNTH on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Dividends and capital return no distribution in twelve months · buybacks 300 m USD in FY2025

Dividends and capital return

What LNTH pays out and buys back — distributions read from the price series, money terms from the filings.

  • Distributions No cash distribution recorded in the price series over the last three years
  • Buybacks, FY2025 300 m USD 4.6% of today's market value
  • Share count −4.5% in FY2025 86 m USD of stock-based compensation in the year
  • Capital returned 300 m USD · 85% of free cash flow dividends and buybacks together, against the year’s free cash flow

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 55/100 · S&P 500 fund at 58, above its 50- and 200-day averagesEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-17
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 94th percentile of the window, +2.7% over 20 sessions. Factor regime → 2026-09-17
  • Sovereign pressure Index 0.00 · down 0.41 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-17

FAQ · from the current data · as of 2026-09-18

Quick answers

What is Lantheus Holdings Inc (LNTH)?

Lantheus Holdings Inc trades as LNTH on the US exchange (US) in the Closelook research universe, as of the registry build of 2026-09-18.

Is LNTH in a Closelook index?

Not currently — Lantheus Holdings Inc is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-18.

Where does LNTH trade against its moving averages?

Pullback inside an uptrend stack: Trades -1.1% vs the 50-day and +17.2% vs the 200-day average, 9.9% below the 52-week high and +102.9% off the 52-week low. Computed from daily closes. As of 2026-09-17 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does Lantheus Holdings Inc do?

Lantheus develops diagnostic and therapeutic products used in imaging and treating heart disease, cancer and other conditions. Its portfolio includes DEFINITY for echocardiography, TechneLite and Xenon-133 for nuclear medicine, and PYLARIFY, a PET imaging agent used to detect prostate cancer. It also markets RELISTOR for opioid-induced constipation and develops several radiopharmaceutical therapy candidates still in testing. Closelook's peer group is not set for this name; the comparison the market draws is with Novartis's radioligand therapy business.

Where does Lantheus Holdings Inc sit in the AI build-out?

Lantheus sits outside our AI build-out index; it belongs to the healthcare sector, within the specialty pharmaceuticals and diagnostic imaging sleeve of our wider universe. Lantheus holds no seat in our indices and carries no Closelook score yet; the diary has not quoted it in any edition.

Does Lantheus Holdings Inc pay a dividend?

No cash distribution shows in Lantheus Holdings Inc’s price series over the last three years. In fiscal 2025 the company bought back 300 m USD of its own shares, 85% of that year’s free cash flow. The share count fell 4.5% over the fiscal year. The "Dividends and capital return" block on this page carries the lines.

What has Wall Street done on Lantheus Holdings Inc recently?

The most recent analyst action on Lantheus Holdings Inc on the Closelook wire is a downgrade by B. Riley on 2026-08-17 (Buy → Neutral). 1 action on the analyst wire since 2026-08-13: 1 downgrade. Analyst actions are third-party opinions recorded by the wire, not Closelook readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for LNTH, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe

then Drug Manufacturers - Specialty & Generic. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.